Peter EICKELMANN,Michael MARK,Leo John SEMAN,Leo THOMAS,Uli Christian BROEDL,Rolf GREMPLER
申请号：
US16452719
公开号：
US20200085851A1
申请日:
2019.06.26
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions
